Amy Browning, APRN, and Theresa Bryant, LPN: The Safety Profile of CAR T Therapy

Msses. Browning and Bryant discuss how adverse events, including neurotoxicity and cytokine release syndrome, can manifest in patients with multiple myeloma who receive chimeric antigen receptor T-cell (CAR T) therapy. They describe how to spot neurotoxicity, and how this adverse effect can present differently in each patient. Additionally, they share their experiences treating these patients, and they stress the importance of patient and care partner education in order to diagnose and treat adverse effects in a timely manner.

Topics covered:

The safety profile of CAR T therapy, including neurotoxicity and CRS
Atypical presentations of neurotoxicity following CAR T therapy
Education of patients and care partners on potential adverse effects

MORE MULTIPLE MYELOMA ROUNDTABLES:

Benefits of Early CAR T-Cell Therapy in Multiple Myeloma

Stephanie Gregory, MS, FNP-C, BMTCN, and Jacob Bartlett, PA-C, from Northside Hospital discuss the clinical advantages of utilizing CAR T-cell therapy in earlier lines of treatment for multiple myeloma. They emphasize that early intervention, facilitated by prompt referrals to specialized centers, can lead to more durable remissions and a better quality of life for patients by utilizing their T-cells before they become exhausted by multiple prior treatments.